# N4 Pharma plc Nuvec® R&D and Strategy Update

- Link: https://www.directorstalkinterviews.com/n4-pharma-plc-nuvec%c2%ae-rd-and-strategy-update/4121135354
- Published: 2023-12-07T07:19:39+00:00
- Author: Ethan Davis

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has provided an encouraging
update on its ongoing _in vitro_ siRNA research work.

The Company’s double loaded siRNA work is ongoing and the Board wishes to provide
an update on the progress achieved so far, as we reach the end of 2023.  The work
to date is very encouraging and is demonstrating that Nuvec® has considerable potential
to be able to knockdown two independent pathways leading to more effective cancer
treatments by reducing the ability for tumour escape.

**_Nuvec_**_®_ **_R&D_**

For the past few months, the Company has been investigating the ability of Nuvec
® nanoparticles to be loaded with, and deliver at the same time, two different siRNA
known to inhibit relevant oncology targets. This is cutting edge research in the
use of nanoparticles as delivery systems in oncology and consequently the Company
is proceeding carefully to ensure that it gains the maximum understanding of the
cellular processes involved.

Using multiple different siRNA constructs has demonstrated that two separate siRNA
can be loaded onto Nuvec® without changing the size or charge of Nuvec®, both parameters
being essential for successful cellular uptake.

The initial work on cell growth involved investigating the combination of inhibition
of EGFR (epidermal growth factor receptor) and _BCL__–__2__:_ (B-cell lymphoma 2)
using PC-9 cancer cells.  As previously announced, each siRNA when separately loaded
onto Nuvec® achieved cell inhibition and an assay to measure BCL-2 had been established.
Subsequent work has confirmed that the expression level of BCL-2 in PC9 cells was
at the limits of detection, and consequently unlike with EGFR, a knockdown response
curve could not be measured.

In view of the low BCL-2 expression, the Company has been investigating alternative
cellular pathways that may be inhibited using siRNA loaded alongside EGFR. The first
was BRD4 (Bromodomain-containing-protein 4) a target for which inhibitors are currently
being evaluated in clinical trials in uveal melanoma, leukemia and carcinoma. The
second target was PLK1 (Polo Like Kinase 1), inhibitors of which are in early clinical
trials for lymphoma and pancreatic cancer. Additional targets may also be explored
as the Company’s work progresses.

As with the other siRNAs explored to date, Nuvec® can be loaded with the individual
SiRNA and effect knockdown of the respective targets and reduce cell viability in
a dose related manner.

Having confirmed dual loading of Nuvec®, the Company subsequently tested the effect
of BRD4 combined with EGFR and PLK1 combined with EGFR on knockdown and cell viability.
Although individually both siRNA had demonstrated the expected results of a dose
dependent inhibition of cell growth and target knockdown, when loaded together there
was an interaction which resulted in a reduction in knockdown of EGFR receptor but
importantly the reduction on cell viability was retained.

The mechanism responsible for the interaction between two separate siRNA on target
knockdown, when loaded on Nuvec® is under investigation. One explanation is that
there is not a correlation between the degree of knockdown and the functional effect
on cell death. In particular, the Company is exploring varying the amount of each
siRNA loaded on Nuvec® to see how these change the degree of interaction whilst 
also maintaining cellular inhibition. Investigations will also be undertaken to 
see how low the dose can be reduced to still achieve a functional cell inhibition
endpoint as dose sparing could be another useful advantage when using Nuvec®.

**_Oncology Strategy_**

It is likely that the precise combinations of siRNA, both in terms of target and
concentration of siRNA, will vary depending in which cell type they are tested in.
Both these elements will be determined by the clinical outcome desired.

Chemotherapy treatments for cancers are broad stroked and have very high toxicity
which has led to the emergence of alternative immuno-oncology treatments.  These
have had remarkable success for some cancers but have proved ineffective in curbing
the progression of numerous cancers. Single pathway treatments can have an initial
effect but many see the post treatment emergence of cancer cells that have developed“
immune escape” pathways leaving retreatment as futile.

Novel approaches to treatment of cancer that do not rely on the immune response,
nor incur the general toxicity induced by chemotherapy or radiotherapy, but rather
rely on targeting the well-known growth factor pathways spurring tumour growth are
key to addressing the shortfalls of immunotherapeutic and chemotherapeutic approaches.
Although some monoclonal antibody treatments (mAbs) do target tumour growth dependent
pathways, they have highly significant off target effects, must be given repetitively,
can be immunogenic, and target only one pathway at a time, allowing for emergence
of tumour populations that proliferate by other growth pathways. None have been 
curative.

The work the Company is doing shows that Nuvec® can bind not only single, but multiple
siRNAs aimed at simultaneously targeting identified pathways responsible for cancer
progression after initial treatments. Knocking down both (or more) pathways will
give a greater chance that tumours will not develop resistance, escape and again
proliferate by the emergence of a significant alternative growth pathway, which 
is common in treatments blocking just one growth factor pathway.

The _in vitro_ findings are highlighting the complex nature of multiple pathway 
targeting and the Company we will look at further _in vivo_ studies and their scope
as this work concludes whilst, in parallel, supplying potential collaborators with
_in vitro_ data as it is gathered.

The Company’s oral and AAV viral vector work is also ongoing and further updates
will be provided in due course, along with news regarding the recent acquisition
of a controlling interest in Nanogenics Limited.

> **Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:**
> _“__There has been a lot of work undertaken in what is a highly complex scientific
> area and w__e have repeatedly shown that Nuvec® is_ _successful in always loading
> and delivering dual siRNA, however the interactions between the siRNA vary depending
> on which two are chosen and which cells they are tested in so we continue to test
> these interactions._
> _“The work we have done so far is extremely encouraging and is demonstrating that
> Nuvec® has considerable potential to be able to knockdown two independent pathways
> leading to more effective cancer treatments by reducing the ability for tumour
> escape. This is a highly desirous and innovate approach in developing novel cancer
> treatments_.”

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system
for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery
system called Nuvec®.

N4 Pharma’s business model is to partner with companies developing novel antigens
in these fields to use Nuvec® as the delivery vehicle for these antigens. As these
products progress through pre‐clinical and clinical programs, N4 Pharma will seek
to receive upfront payments, milestone payments and ultimately royalty payments 
once products reach the market.

Share on:
